Quantcast

Latest BIBW Stories

2011-05-25 11:28:00

RIDGEFIELD, Conn., May 25 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. will present new phase Ib data at the 2011 American Society of Clinical Oncology (ASCO) annual meeting in Chicago (June 3-7) that indicates combining its investigational therapy afatinib (BIBW 2992) with cetuximab at the maximum tested dose controlled disease in all (n=22) treated epidermal growth factor receptor (EGFR)-mutation positive patients with non-small cell lung cancer (NSCLC) who developed...

2010-12-09 07:45:00

RIDGEFIELD, Conn., Dec. 9, 2010 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced that new data from a subgroup analysis of the phase IIb/III LUX-Lung 1 trial show that afatinib (BIBW 2992) reached a four-fold extension (4.4 months vs. 1.0 month for placebo) in progression-free survival (PFS) in advanced non-small cell lung cancer (NSCLC) patients most likely to have an epidermal growth factor receptor (EGFR) mutation.(1) The updated LUX-Lung 1 data will be presented at...

2010-12-08 08:00:00

RIDGEFIELD, Conn. Dec. 8, 2010 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced the initiation of a phase III clinical trial in the United States to investigate one of its oncology pipeline compounds, afatinib* (BIBW 2992), for the treatment of patients with advanced (metastatic) breast cancer. Afatinib is an investigational orally administered irreversible inhibitor of both the epidermal growth factor receptor (EGFR) and human epidermal receptor 2 (HER2)...

2010-10-11 08:03:00

RIDGEFIELD, Conn., Oct. 11 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today results from two clinical trials for its investigational cancer compound afatinib* (BIBW 2992) presented at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy. In the phase IIb/III LUX-Lung 1 study, afatinib tripled the secondary endpoint of progression free survival (PFS) but did not extend the primary endpoint of overall survival (OS) in late-stage patients...

2010-05-20 17:00:00

RIDGEFIELD, Conn., May 20 /PRNewswire/ -- Boehringer Ingelheim will announce preliminary data in the areas of head and neck cancer and non-small cell lung cancer (NSCLC) for one of the company's investigational compounds, BIBW 2992. These data will be presented at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. BIBW 2992 is an orally-administered small molecule under development that irreversibly inhibits the epidermal growth factor...

2009-08-03 07:00:00

RIDGEFIELD, Conn., Aug. 3 /PRNewswire/ -- Boehringer Ingelheim announced today at the International Association for the Study of Lung Cancer's 13th World Conference on Lung Cancer (WCLC), San Francisco, CA, the initiation of a Phase III clinical study of BIBW 2992 as first-line treatment in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. BIBW 2992 is the first orally-administered irreversible dual inhibitor of EGFR and HER2,(1) to reach...

2009-05-14 17:17:00

- Data on BIBW 2992, an Irreversible, Dual EGFR / HER2 Tyrosine Kinase Inhibitor, Suggests Activity in Second-line Treatment of NSCLC Patients with EGFR Activating Mutations - (1,2) -The First Presentation of Data on BIBF 1120 in Ovarian Cancer- RIDGEFIELD, Conn., May 14 /PRNewswire/ -- Boehringer Ingelheim will present new data on the company's two lead oncology compounds, BIBW 2992 and BIBF 1120 at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO), the company...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.